trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Nasal and oral sprays effectively neutralize airborne viruses

the verdict
SUPPORTED
the evidence backs this
Recorded sources
6 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that nasal and oral sprays effectively neutralize airborne viruses?

Yes. Multiple preclinical and clinical studies demonstrate that specialized nasal and oral sprays can effectively trap, neutralize, or prevent the replication of airborne viruses in the upper respiratory tract.

Verdict: SUPPORTED · 6 sources for, 0 against · Last checked

The analysis

The retrieved literature consistently supports the claim that various formulations of nasal sprays (including antiviral polymers, immune agonists, and engineered fusion proteins) can successfully neutralize or reduce airborne viral loads and shedding in the upper respiratory tract.

Evidence for · 6
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model
2020
Demonstrates that prophylactic intranasal administration of a TLR2/6 agonist significantly reduces viral shedding in the upper respiratory tract.
Get citation
Proud, P., Tsitoura, D., Watson, R. J., Chua, B., Aram, M., Bewley, K., Cavell, B. E., Cobb, R., Dowall, S., Fotheringham, S., Ho, C. M. K., Lucas, V., Ngabo, D., Rayner, E., Ryan, K., Slack, G. S., Thomas, S. R., Wand, N. I., Yeates, P., Demaison, C., Zeng, W., Holmes, I., Jackson, D., Bartlett, N., Mercuri, F., & Carroll, M. (2020). Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. doi.org. https://doi.org/10.1016/j.ebiom.2020.103153

See more details
More for · 5
Formulation of a Composite Nasal Spray Enabling Enhanced Surface Coverage and Prophylaxis of SARS‐COV‐2
2021
Shows that polysaccharide-based nasal sprays can physically entrap and inhibit SARS-CoV-2 infection in cells.
Get citation
Moakes, R., Davies, S., Stamataki, Z., & Grover, L. (2021). Formulation of a Composite Nasal Spray Enabling Enhanced Surface Coverage and Prophylaxis of SARS‐COV‐2. doi.org. https://doi.org/10.1002/adma.202008304

Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice
2021
Indicates that astodrimer sodium 1% nasal spray successfully reduces viral replication and shedding in animal models.
Get citation
Paull, J., Luscombe, C., Castellarnau, A., Heery, G. P., Bobardt, M., & Gallay, P. (2021). Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice. doi.org. https://doi.org/10.3390/v13081656

Nasal residence time and rheological properties of a new bentonite-based thixotropic gel emulsion nasal spray – AM-301
2023
Establishes that a thixotropic gel emulsion nasal spray can provide extended coverage and residence time in the nasal cavity to block pathogens.
Get citation
Sailer, M. M., Köllmer, M., Masson, B., Fais, F., Hohenfeld, I. P., Herbig, M. E., Koitschev, A., & Becker, S. (2023). Nasal residence time and rheological properties of a new bentonite-based thixotropic gel emulsion nasal spray – AM-301. doi.org. https://doi.org/10.1080/03639045.2023.2183724

Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study
2023
Clinical study showing that an engineered IgM-like ACE2 fusion protein nasal spray accelerates viral clearance in SARS-CoV-2-infected patients.
Get citation
Song, R., Chen, X., Li, B., Zhang, H., Guo, X., Liu, Z., Zou, L., Liang, X., Lei, C., Mao, F., Sui, J., Li, W., & Jin, R. (2023). Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study. doi.org. https://doi.org/10.1002/jmv.28805

Toward a Radically Simple Multi‐Modal Nasal Spray for Preventing Respiratory Infections
2024
Presents a multi-modal Pathogen Capture and Neutralizing Spray that effectively captures and neutralizes respiratory viruses.
Get citation
Joseph, J., Baby, H. M., Quintero, J. R., Kenney, D. J., Mebratu, Y., Bhatia, E., Shah, P., Swain, K., Lee, D., Kaur, S., Li, X., Mwangi, J., Snapper, O., Nair, R., Agus, E., Ranganathan, S., Kage, J., Gao, J., Luo, J. N., Yu, A., Park, D. T., Douam, F., Tesfaigzi, Y., Karp, J. M., & Joshi, N. (2024). Toward a Radically Simple Multi‐Modal Nasal Spray for Preventing Respiratory Infections. doi.org. https://doi.org/10.1002/adma.202406348

Related receipts

What does the evidence say?

The retrieved literature consistently supports the claim that various formulations of nasal sprays (including antiviral polymers, immune agonists, and engineered fusion proteins) can successfully neutralize or reduce airborne viral loads and shedding in the upper respiratory tract.

Receipt History
first checked04 Aug 2026
judged → SUPPORTED · 8704 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work